Company: OnKure Inc.
Job title: Vice President - Biology & Translational Medicine
OKI-179, an Oral Class 1-selective Depsipeptide HDAC Inhibitor: Phase 1 Results & Phase 2 Plans 1:00 pm
OKI-179 is an oral depsipeptide HDAC Class 1 inhibitor, the same class as the IV drug romidepsin Demonstrating how OKI-179 has completed Phase 1 with excellent PK, PD and safety Discussing a molecular approach to Phase 2 trialsRead more
day: Day One